Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of gamabufotalin to angiogenesis inhibiting medicine preparation and pharmaceutical preparation of gamabufotalin

A technology of bufafetalin and pharmaceutical preparations, which is applied in the field of pharmaceutical preparations, can solve the problems of no bufafetalin and other problems, achieve the effect of inhibiting angiogenesis, inhibiting angiogenesis, and has a broad market prospect

Inactive Publication Date: 2016-03-02
DALIAN MEDICAL UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no related report that jenobubafalin can inhibit tumor angiogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gamabufotalin to angiogenesis inhibiting medicine preparation and pharmaceutical preparation of gamabufotalin
  • Application of gamabufotalin to angiogenesis inhibiting medicine preparation and pharmaceutical preparation of gamabufotalin
  • Application of gamabufotalin to angiogenesis inhibiting medicine preparation and pharmaceutical preparation of gamabufotalin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1. Inhibitory effect of bufatolin on angiogenesis induced by VEGF.

[0043] Implementation method (tube formation experiment): primary HUVEC cells were cultured according to conventional methods, and the cells growing in the logarithmic phase of the first three generations were collected and counted, and 50 μl of cells containing different concentrations of bufafetalin and VEGF (50ng / mL) Suspension (1×10 4 cells), seeded in Angiogenesis slides pre-added with Matrigel, 5% CO 2 Incubate at 37°C for 6 hours in an incubator. The inhibitory effect of bufafetalin on tube formation was observed under a microscope. Such as image 3 As shown, bufafetoxin can significantly inhibit VEGF-induced angiogenesis.

[0044] Implementation method (aortic ring experiment): the aorta was isolated from black C57 / BL6 mice, cleaned and cut into 1mm aortic rings. Embed aortic rings in collagen gel, inoculate into 48 empty plates, and store in 5% CO 2 Incubate at 37°C for 0.5h in...

Embodiment 2

[0046] Example 2 Bufatalin has effects on multiple myeloma cells cultured in vitro, myeloma patients CD138 + cells and the inhibitory effect on B cells from healthy volunteers

[0047] Implementation method (MTT method): Multiple myeloma cells (MM1.S, RPMI8226, OPM2) were cultured and passaged according to conventional methods, and cells growing in the logarithmic phase were collected, as well as CD138 cells isolated from myeloma patients or healthy volunteers. + Cells or B cells, counted, and the volume of cell fluid per well was 100 μl and seeded in a 96-well plate in 5% CO 2 Incubate at 37°C for 12 hours in an incubator. Set 7 concentrations of the active ingredient Ribuba toadalin extracted from Chansu, and set 6 replicate wells for each concentration, culture in a 5% CO2 incubator at 37°C for 48 hours, and add 5mg / mLMTT. After incubation at 37°C for 4 hours, discard the supernatant, add 150mL DMSO to dissolve, measure the absorbance value with a microplate reader ...

Embodiment 3

[0048] Example 3. The inhibitory effect of bufabutalin on the growth of multiple myeloma MM1.S and RPMI8226 tumor-bearing mice and the effect of improving the survival rate of mice.

[0049] Drug dissolution: 30% propylene glycol for injection dissolves bufafetalin and dilutes it to the required concentration for experimentation.

[0050] SPF grade CB.17SCID mice weighing 18-20 g were used.

[0051] Tumor cell inoculation: take MM1.S and RPMI8226 cells in logarithmic growth phase, and prepare cell suspension (5×10 7 per mL), implanted subcutaneously in the armpit of the right forelimb of the mouse (0.1 mL per mouse), and the mental state, diet and defecation of the mice were observed every day after inoculation.

[0052] Grouping and administration: The subcutaneous transplanted tumor reached about 3×4mm, and the mice with the same tumor size were selected, weighed and divided into random groups. There were two dose groups: blank control group, 0.5 mg / Kg and 1 mg / Kg of bufa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of gamabufotalin to angiogenesis inhibiting medicine preparation and particularly provides application of the gamabufotalin to vascular endothelial growth inhibiting medicine preparation. A research result that the gamabufotalin is capable of inhibiting angiogenesis obviously both in vivo and in vitro is put forward firstly herein. The invention further discloses a pharmaceutical preparation. The pharmaceutical preparation is prepared from a therapeutic dose of gamabufotalin and pharmaceutical compositions thereof as well as one or more pharmaceutically acceptable excipients, and is capable of inhibiting angiogenesis. Modernized studies on traditional Chinese medicine in China are involved to promote active ingredients deriving from traditional Chinese medicines to be used for non-solid tumor treatment and new traditional Chinese medicine development, thus, the gamabufotalin has lots of advantages and is suitably popularized in and applied to the field and quite promising in market prospect.

Description

technical field [0001] The present invention relates to a specific application of jenobubafalin, in particular to the application of jenobubafalin in the preparation of drugs for inhibiting angiogenesis, and the pharmaceutical preparation prepared by using jenobubafalin. Background technique [0002] Tumors can be clinically divided into solid tumors and non-solid tumors. Solid tumors are tangible tumors, which can be palpated through clinical examinations such as X-ray films, CT scans, B-ultrasound, or palpation. Solid tumors are called solid tumors (such as Lung cancer, breast cancer, liver cancer, etc.); non-solid tumors (liquid tumors), which are X-ray, CT scans, B-ultrasound and palpable tumors that cannot be seen or touched are non-solid tumors, such as leukemia in blood diseases, Malignant lymphoma, multiple myeloma, etc. At present, surgery cannot be used for the treatment of non-solid tumors, and a combination of chemotherapy and drugs is often used. Clinical chem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/585A61P35/00
Inventor 马骁驰于振龙王超汤宁张宝璟黄珊珊邓卅
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com